Company Profiles

driven by the PitchBook Platform

Oxyrane

Oxyrane
2006 FOUNDED
PRIVATE STATUS
Series E LATEST DEAL TYPE
$29.9M LATEST DEAL AMOUNT
$61.3M TOTAL AMOUNT RAISED
3 INVESTORS
Description

Developer of enzyme replacement therapies for lysosomal storage diseases. The company's enzyme replacement therapies are use to cure lysososomal storage diseases using a proprietary glycoengeneering expression host based on the yeast Yarrowia lipolytica, enabling patients to begin treatment more quickly and result in a higher likelihood of a successful treatment.

Website:
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Drug Discovery
Biotechnology
Primary Office
Suite 313, Piccadilly House
49 Piccadilly
Manchester M1 2AP
England

+44 (0)16 1232 6000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Oxyrane’s full profile, request a free trial.

Oxyrane Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series E) 04-Aug-2014 $29.9M $61.3M 000.00 Completed Generating Revenue/Not Profitable
4. Later Stage VC (Series D) 23-Aug-2011 000.00 000.00 0000 Completed Generating Revenue/Not Profitable
3. Later Stage VC (Series C) 22-Jul-2011 00.000 000.00 000.00 Completed Generating Revenue/Not Profitable
2. Later Stage VC 01-Jun-2011 $14.1M $14.1M $28.8M Completed Generating Revenue/Not Profitable
1. Early Stage VC 12-Jun-2007 Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Oxyrane Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series E 0,000,000 00.000000 000.00 00.00 00.00 00 00.00 00.000
Series D2 0,000,000 00.000000 000.00 00.00 00.00 00 00.00 00.000
Series D1 0,000,000 00.000000 000.00 00.00 00.00 00 00.00 00.000
Series C2 000,000 00.000000 000.00 00.00 00.00 00 00.00 0.000
Series C1 000,000 00.000000 000.00 00.00 00.00 00 00.00 0.000
Series B3 000,000 00.000000 000.00 00.00 00.00 00 00.00 0.000
Series B1 000,000 00.000000 000.00 00.00 00.00 00 00.00 0.000
Series A2 493,776 $0.001671 $13.37 $8.36 $8.36 1x $8.36 2.61%
Series A1 197,509 $0.001671 $13.37 $0.02 $0.02 1x $0.02 1.04%
To view this company’s complete Cap Table request access »

Oxyrane Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Forbion Capital Partners Venture Capital Minority 000 0000 000000 0
Morningside Group Venture Capital Minority 000 0000 000000 0
New Science Ventures Venture Capital Minority 000 0000 000000 0

Oxyrane Executive Team (3)

Name Title Board
Seat
Contact
Info
Everhardus Küppers Chief Executive Officer & Board Member
Wouter Vervecken Ph.D Chief Scientific Officer
Taennler Simon Head, Fermentation

Oxyrane Board Members (13)

Name Representing Role Since Contact
Info
Charlie Richard III Oxyrane Board Member 000 0000
Christopher Bull Self Director 000 0000
Everhardus Küppers Oxyrane Chief Executive Officer & Board Member 000 0000
Gerald Chan Ph.D Morningside Group Director 000 0000
Hans Preusting Oxyrane Board Member 000 0000

1 Former Board Members

You’re viewing 5 of 13 board members. Get the full list »